Search results
Results from the WOW.Com Content Network
This list of over 500 monoclonal antibodies includes approved and ... Name Brand name Type Source ... Durvalumab [25] Imfinzi: mab: human: PD-L1: Y: cancer ...
Avelumab (Bavencio) is a fully human IgG1 antibody developed by Merck Serono and Pfizer. Avelumab is FDA approved for the treatment of metastatic merkel-cell carcinoma. It failed phase III clinical trials for gastric cancer. [33] Durvalumab (Imfinzi) is a fully human IgG1 antibody developed by AstraZeneca.
Durvalumab, [11] sold under the brand name Imfinzi, is an anti-cancer medication used for treatment of various types of cancer. [9] It was developed by Medimmune / AstraZeneca . [ 12 ] It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 ( PD-L1 ).
Imfinzi is a human monoclonal antibody, which works to block a tumour's ability to evade and dampen the immune system, while also boosting the body's anti-cancer immune response, offering an ...
(Reuters) -Eli Lilly has cut the price for vials of its weight-loss drug Zepbound sold online and expanded the range of doses in an attempt to stave off stiff competition from compounding ...
Pembrolizumab (brand name Keytruda) is another PD-1 inhibitor that was approved by the FDA in 2014 and was the second checkpoint inhibitor approved in the United States. [17] Keytruda is approved to treat melanoma and lung cancer and is produced by Merck .
The approval from the U.S. Food and Drug Administration came after a late stage trial showed that Imfinzi along with chemotherapy drugs carboplatin and paclitaxel, then followed by Imfinzi by ...
Tremelimumab, sold under the brand name Imjudo, is a fully human monoclonal antibody used for the treatment of hepatocellular carcinoma (a type of liver cancer). [7] [8] Tremelimumab is designed to attach to and block CTLA-4, a protein that controls the activity of T cells, which are part of the immune system (the body’s natural defenses).